Ticking all boxes as far as I can see. Plenty of cash in hand for the next set of trials, with a very low market cap of 81 million, 34 mill cash
(Invex’s proposed preclinical and human pharmacokinetic approach was acceptable to both EMA and FDA)
(Invex to optimise the registration strategy for both EU and US over the coming weeks)
Everything is on track, and I see the recent pull back as a great chance to top up. Not to forget this team has no intentions to take this to market, it’s a straight out buy from a large pharmaceutical company when the time is right. AIMHO
Ticking all boxes as far as I can see. Plenty of cash in hand...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.411M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 158 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.12pm 25/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable